<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB02034</drugbank-id>
  <drugbank-id>EXPT02983</drugbank-id>
  <drugbank-id>DB06425</drugbank-id>
  <name>Tridolgosir</name>
  <description>An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.</description>
  <cas-number>72741-87-8</cas-number>
  <unii>RSY4RK37KQ</unii>
  <average-mass>173.2096</average-mass>
  <monoisotopic-mass>173.105193351</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A6848</ref-id>
        <pubmed-id>16034517</pubmed-id>
        <citation>Shaheen PE, Stadler W, Elson P, Knox J, Winquist E, Bukowski RM: Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest New Drugs. 2005 Dec;23(6):577-81.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>William H. Pearson, Erik J. Hembre, "Method for preparing swainsonine." U.S. Patent US5919952, issued December, 1986.</synthesis-reference>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action>Tridolgosir competitively inhibits the alpha manosidase II (alphaMII), which processes N linked carbohydrates of newly synthesized glycoproteins passing through the Golgi apparatus to the cell surface. Highly branched carbohydrate structures are created which bind to Lectin-phytohemagglutinin (L-PHA) and are subsequently expressed in different tumor types which results in metastatic phenotype, which is correlated with an increased aggressiveness in animals and causes other human malignancies. Inhibition of alphaMII reduces carbohydrates that bind to L-PHA, reducing aggressiveness, metastatic phenotype cells, slows tumor growth, and increases“hybrid type” carbohydrates on the cell surface. Hybrid type carbohydrates may increase cytokine activation of lymphocytes, increasing tumor susceptibility to lymphokine activated and natural killer cells.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as indolizidines. These are polycyclic compounds containing an indolizidine, which is a bicyclic heterocycle containing a saturated six-member ring fused to a saturated five-member ring, one of the bridging atoms being nitrogen.</description>
    <direct-parent>Indolizidines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Indolizidines</class>
    <subclass/>
    <alternative-parent>1,2-aminoalcohols</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>N-alkylpyrrolidines</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Piperidines</alternative-parent>
    <alternative-parent>Polyols</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>1,2-aminoalcohol</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic heteropolycyclic compound</substituent>
    <substituent>Amine</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Indolizidine</substituent>
    <substituent>N-alkylpyrrolidine</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Piperidine</substituent>
    <substituent>Polyol</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001877</drugbank-id>
      <name>Tridolgosir hydrochloride</name>
      <unii>78KR51ES9B</unii>
      <cas-number>214462-68-7</cas-number>
      <inchikey>LIRVFCZWYJVKCV-XNJRRJNCSA-N</inchikey>
      <average-mass>209.67</average-mass>
      <monoisotopic-mass>209.0818711</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">(1S,2R,8R,8AR)-octahydro-1,2,8-indolizinetriol</synonym>
    <synonym language="english" coder="">Swainosine</synonym>
    <synonym language="english" coder="inn">Tridolgosir</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1hww</pdb-entry>
    <pdb-entry>2ww0</pdb-entry>
    <pdb-entry>2ww2</pdb-entry>
    <pdb-entry>2wyi</pdb-entry>
    <pdb-entry>3blb</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>0.88</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.32e+03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>swainsonine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>173.2096</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>173.105193351</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@@]1(O)CN2CCC[C@@]([H])(O)[C@]2([H])[C@]1([H])O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C8H15NO3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2/t5-,6-,7-,8-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>FXUAIOOAOAVCGD-WCTZXXKLSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>63.93</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>43.12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>17.84</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>13.28</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.47</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>143-144 °C</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>9367</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>51683</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506581</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C10173</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>46788</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50168995</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>SWA</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Swainsonine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL371197</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0003505</id>
      <name>Alpha-mannosidase 2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A1991</ref-id>
            <pubmed-id>10592235</pubmed-id>
            <citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q16706" source="Swiss-Prot">
        <name>Alpha-mannosidase 2</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Catalyzes the first committed step in the biosynthesis of complex N-glycans. It controls conversion of high mannose to complex N-glycans; the final hydrolytic step in the N-glycan maturation pathway.</specific-function>
        <gene-name>MAN2A1</gene-name>
        <locus/>
        <cellular-location>Golgi apparatus membrane</cellular-location>
        <transmembrane-regions>6-26</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.61</theoretical-pi>
        <molecular-weight>131139.485</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6824</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>MAN2A1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D63998</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q16706</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MA2A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.2.1.114</synonym>
          <synonym>AMan II</synonym>
          <synonym>Golgi alpha-mannosidase II</synonym>
          <synonym>Man II</synonym>
          <synonym>MANA2</synonym>
          <synonym>Mannosidase alpha class 2A member 1</synonym>
          <synonym>Mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012442|Alpha-mannosidase 2
MKLSRQFTVFGSAIFCVVIFSLYLMLDRGHLDYPRNPRREGSFPQGQLSMLQEKIDHLER
LLAENNEIISNIRDSVINLSESVEDGPKSSQSNFSQGAGSHLLPSQLSLSVDTADCLFAS
QSGSHNSDVQMLDVYSLISFDNPDGGVWKQGFDITYESNEWDTEPLQVFVVPHSHNDPGW
LKTFNDYFRDKTQYIFNNMVLKLKEDSRRKFIWSEISYLSKWWDIIDIQKKDAVKSLIEN
GQLEIVTGGWVMPDEATPHYFALIDQLIEGHQWLENNIGVKPRSGWAIDPFGHSPTMAYL
LNRAGLSHMLIQRVHYAVKKHFALHKTLEFFWRQNWDLGSVTDILCHMMPFYSYDIPHTC
GPDPKICCQFDFKRLPGGRFGCPWGVPPETIHPGNVQSRARMLLDQYRKKSKLFRTKVLL
APLGDDFRYCEYTEWDLQFKNYQQLFDYMNSQSKFKVKIQFGTLSDFFDALDKADETQRD
KGQSMFPVLSGDFFTYADRDDHYWSGYFTSRPFYKRMDRIMESHLRAAEILYYFALRQAH
KYKINKFLSSSLYTALTEARRNLGLFQHHDAITGTAKDWVVVDYGTRLFHSLMVLEKIIG
NSAFLLILKDKLTYDSYSPDTFLEMDLKQKSQDSLPQKNIIRLSAEPRYLVVYNPLEQDR
ISLVSVYVSSPTVQVFSASGKPVEVQVSAVWDTANTISETAYEISFRAHIPPLGLKVYKI
LESASSNSHLADYVLYKNKVEDSGIFTIKNMINTEEGITLENSFVLLRFDQTGLMKQMMT
KEDGKHHEVNVQFSWYGTTIKRDKSGAYLFLPDGNAKPYVYTTPPFVRVTHGRIYSEVTC
FFDHVTHRVRLYHIQGIEGQSVEVSNIVDIRKVYNREIAMKISSDIKSQNRFYTDLNGYQ
IQPRMTLSKLPLQANVYPMTTMAYIQDAKHRLTLLSAQSLGVSSLNSGQIEVIMDRRLMQ
DDNRGLEQGIQDNKITANLFRILLEKRSAVNTEEEKKSVSYPSLLSHITSSLMNHPVIPM
ANKFSSPTLELQGEFSPLQSSLPCDIHLVNLRTIQSKVGNGHSNEAALILHRKGFDCRFS
SKGTGLFCSTTQGKILVQKLLNKFIVESLTPSSLSLMHSPPGTQNISEINLSPMEISTFR
IQLR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012443|Alpha-mannosidase 2 (MAN2A1)
ATGAAGTTAAGCCGCCAGTTCACCGTGTTCGGCAGTGCGATCTTCTGTGTGGTGATTTTC
TCGCTCTACCTGATGCTGGACCGGGGTCACTTAGACTACCCCAGGAACCCGCGCCGCGAG
GGCTCCTTCCCTCAGGGCCAGCTCTCAATGTTGCAAGAAAAAATAGACCATTTGGAGCGT
TTGCTAGCTGAGAATAATGAGATCATCTCAAATATTAGAGACTCAGTCATCAATTTGAGT
GAGTCTGTGGAGGATGGTCCGAAAAGTTCACAAAGCAATTTCAGCCAAGGTGCTGGCTCA
CATCTTCTGCCCTCACAATTATCCCTCTCAGTTGACACTGCAGACTGTCTGTTTGCTTCA
CAAAGTGGAAGTCACAATTCAGATGTGCAGATGTTGGATGTTTACAGTCTAATTTCTTTT
GACAATCCAGATGGTGGAGTTTGGAAGCAAGGATTTGACATTACTTATGAATCTAATGAA
TGGGACACTGAACCCCTTCAAGTCTTTGTGGTGCCTCATTCCCATAACGACCCAGGTTGG
TTGAAGACTTTCAATGACTACTTTAGAGACAAGACTCAGTATATTTTTAATAACATGGTC
CTAAAGCTGAAAGAAGACTCACGGAGGAAGTTTATTTGGTCTGAGATCTCTTACCTTTCA
AAGTGGTGGGATATTATAGATATTCAGAAGAAGGATGCTGTTAAAAGTTTAATAGAAAAT
GGTCAGCTTGAAATTGTGACAGGTGGCTGGGTTATGCCTGATGAAGCTACTCCACATTAT
TTTGCCTTAATTGATCAACTAATTGAAGGACATCAGTGGCTGGAAAATAATATAGGAGTG
AAACCTCGGTCCGGCTGGGCTATTGATCCCTTTGGACACTCACCAACAATGGCTTATCTT
CTAAACCGTGCTGGACTTTCTCACATGCTTATCCAGAGAGTTCATTATGCAGTTAAAAAA
CACTTTGCACTGCATAAAACATTGGAGTTTTTTTGGAGACAGAATTGGGATCTGGGATCT
GTCACAGATATTTTATGCCACATGATGCCCTTCTACAGCTATGACATCCCTCACACTTGT
GGACCTGATCCTAAAATATGCTGCCAGTTTGATTTTAAACGTCTTCCTGGAGGCAGATTT
GGTTGTCCCTGGGGAGTCCCCCCAGAAACAATACATCCTGGAAATGTCCAAAGCAGGGCT
CGGATGCTACTAGATCAGTACCGAAAGAAGTCAAAGCTTTTTCGTACCAAAGTTCTCCTG
GCTCCACTAGGAGATGATTTCCGCTACTGTGAATACACGGAATGGGATTTACAGTTTAAG
AATTATCAGCAGCTTTTTGATTATATGAATTCTCAGTCCAAGTTTAAAGTTAAGATACAG
TTTGGAACTTTATCAGATTTTTTTGATGCGCTGGATAAAGCAGATGAAACTCAGAGAGAC
AAGGGCCAATCGATGTTCCCTGTTTTAAGTGGAGATTTTTTCACTTATGCCGATCGAGAT
GATCATTACTGGAGTGGCTATTTTACATCCAGACCCTTTTACAAACGAATGGACAGAATC
ATGGAATCTCATTTAAGGGCTGCTGAAATTCTTTACTATTTCGCCCTGAGACAAGCTCAC
AAATACAAGATAAATAAATTTCTCTCATCATCACTTTACACGGCACTGACAGAAGCCAGA
AGGAATTTGGGACTGTTTCAACATCATGATGCTATCACAGGAACTGCAAAAGACTGGGTG
GTTGTGGATTATGGTACCAGACTTTTTCATTCGTTAATGGTTTTGGAGAAGATAATTGGA
AATTCTGCATTTCTTCTTATTTTGAAGGACAAACTCACATACGACTCTTACTCTCCTGAT
ACCTTCCTGGAGATGGATTTGAAACAAAAATCACAAGATTCTCTGCCACAAAAAAATATA
ATAAGGCTGAGTGCGGAGCCAAGGTACCTTGTGGTCTATAATCCTTTAGAACAAGACCGA
ATCTCGTTGGTCTCAGTCTATGTGAGTTCCCCGACAGTGCAAGTGTTCTCTGCTTCAGGA
AAACCTGTGGAAGTTCAAGTCAGCGCAGTTTGGGATACAGCAAATACTATTTCAGAAACA
GCCTATGAGATCTCTTTTCGAGCACATATACCGCCATTGGGACTGAAAGTGTATAAGATT
TTGGAATCAGCAAGTTCAAATTCACATTTAGCTGATTATGTCTTGTATAAGAATAAAGTA
GAAGATAGCGGAATTTTCACCATAAAGAATATGATAAATACTGAAGAAGGTATAACACTA
GAGAACTCCTTTGTTTTACTTCGGTTTGATCAAACTGGACTTATGAAGCAAATGATGACT
AAAGAAGATGGTAAACACCATGAAGTAAATGTGCAATTTTCATGGTATGGAACCACAATT
AAAAGAGACAAAAGTGGTGCCTACCTCTTCTTACCTGATGGTAATGCCAAGCCTTATGTT
TACACAACACCGCCCTTTGTCAGAGTGACACATGGAAGGATTTATTCGGAAGTGACTTGC
TTTTTTGACCATGTTACTCATAGAGTCCGACTATACCACATACAGGGAATAGAAGGACAG
TCTGTGGAAGTTTCCAATATTGTGGACATCCGAAAAGTATATAACCGTGAGATTGCAATG
AAAATTTCTTCTGATATAAAAAGCCAAAATAGATTTTATACTGACCTAAATGGGTACCAG
ATTCAACCTAGAATGACACTGAGCAAATTGCCTCTTCAAGCAAATGTCTATCCCATGACC
ACAATGGCCTATATCCAGGATGCCAAACATCGTTTGACACTGCTCTCTGCTCAGTCATTA
GGGGTTTCGAGTTTGAATAGTGGTCAGATTGAAGTTATCATGGATCGAAGACTCATGCAA
GATGATAATCGTGGCCTTGAGCAAGGTATCCAGGATAACAAGATTACAGCTAATCTATTT
CGAATACTACTAGAAAAAAGAAGTGCTGTTAATACGGAAGAAGAAAAGAAGTCGGTCAGT
TATCCTTCTCTCCTTAGCCACATAACTTCTTCTCTCATGAATCATCCAGTCATTCCAATG
GCAAATAAGTTCTCCTCACCTACCCTTGAGCTGCAAGGTGAATTCTCTCCATTACAGTCA
TCTTTGCCTTGTGACATTCATCTGGTTAATTTGAGAACAATACAGTCAAAGGTGGGCAAT
GGGCACTCCAATGAGGCAGCCTTGATCCTCCACAGAAAAGGGTTTGATTGTCGGTTCTCT
AGCAAAGGCACAGGGCTGTTTTGTTCTACTACTCAGGGAAAGATATTGGTACAGAAACTT
TTAAACAAGTTTATTGTCGAAAGTCTCACACCTTCATCACTATCCTTGATGCATTCACCT
CCCGGCACTCAGAATATAAGTGAGATCAACTTGAGTCCAATGGAAATCAGCACATTCCGA
ATCCAGTTGAGGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF09261</identifier>
            <name>Alpha-mann_mid</name>
          </pfam>
          <pfam>
            <identifier>PF01074</identifier>
            <name>Glyco_hydro_38</name>
          </pfam>
          <pfam>
            <identifier>PF07748</identifier>
            <name>Glyco_hydro_38C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cis-Golgi network</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carbohydrate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hydrolase activity, hydrolyzing N-glycosyl compounds</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>in utero embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>liver development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung alveolus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mannose metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrion organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>N-glycan processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neurogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-translational protein modification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein deglycosylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein N-linked glycosylation via asparagine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>respiratory gaseous exchange</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina morphogenesis in camera-type eye</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vacuole organization</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>